Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06742723 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06742723 · ClinicalTrials.gov record · last posted 2026-08-26

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

Study acronym: BaxDuo-Pacific
StatusRecruiting
PhasePhase 3
Started2025-03-03
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

Protocol amendment history 4 changes detected by DataLookout

2026-07-29
Trial sites expanded: 764 → 769 locations
2026-06-27
Trial sites expanded: 761 → 764 locations
2026-06-03
Primary endpoint(s) modified
WasTo determine if baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of ≥ 50% sustained decline in eGFR, kidney failure, Heart Failure events(HF), or CV death.
NowTo determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of ≥ 50% sustained decline in eGFR, kidney failure, Heart Failure events(HF), or CV death.
2026-05-01
Trial sites expanded: 756 → 759 locations
Trial Details
NCT Number NCT06742723
Lead Sponsor AstraZeneca
Conditions Chronic Kidney Disease and Hypertension
Enrollment 5,000 participants
Start Date 2025-03-03
Primary Completion 2029-12-18 (estimated)
Study Completion 2029-12-18 (estimated)
Updated on ClinicalTrials.gov 2026-08-26